Epigenetic pathways can regulate gene expression by controlling and interpreting chromatin modifications. Cancer cells are characterized by altered epigenetic landscapes, and commonly exploit the chromatin regulatory machinery to enforce oncogenic gene expression programs 1 . Although chromatin alterations are, in principle, reversible and often amenable to drug intervention, the promise of targeting such pathways therapeutically has been limited by an incomplete understanding of cancer-specific dependencies on epigenetic regulators. Here we describe a non-biased approach to probe epigenetic vulnerabilities in acute myeloid leukaemia (AML), an aggressive haematopoietic malignancy that is often associated with aberrant chromatin states 2 . By screening a custom library of small hairpin RNAs (shRNAs) targeting known chromatin regulators in a genetically defined AML mouse model, we identify the protein bromodomain-containing 4 (Brd4) as being critically required for disease maintenance. Suppression of Brd4 using shRNAs or the small-molecule inhibitor JQ1 led to robust antileukaemic effects in vitro and in vivo, accompanied by terminal myeloid differentiation and elimination of leukaemia stem cells. Similar sensitivities were observed in a variety of human AML cell lines and primary patient samples, revealing that JQ1 has broad activity in diverse AML subtypes. The effects of Brd4 suppression are, at least in part, due to its role in sustaining Myc expression to promote aberrant self-renewal, which implicates JQ1 as a pharmacological means to suppress MYC in cancer. Our results establish small-molecule inhibition of Brd4 as a promising therapeutic strategy in AML and, potentially, other cancers, and highlight the utility of RNA interference (RNAi) screening for revealing epigenetic vulnerabilities that can be exploited for direct pharmacological intervention.
Epigenetic pathways can regulate gene expression by controlling and interpreting chromatin modifications. Cancer cells are characterized by altered epigenetic landscapes, and commonly exploit the chromatin regulatory machinery to enforce oncogenic gene expression programs 1 . Although chromatin alterations are, in principle, reversible and often amenable to drug intervention, the promise of targeting such pathways therapeutically has been limited by an incomplete understanding of cancer-specific dependencies on epigenetic regulators. Here we describe a non-biased approach to probe epigenetic vulnerabilities in acute myeloid leukaemia (AML), an aggressive haematopoietic malignancy that is often associated with aberrant chromatin states 2 . By screening a custom library of small hairpin RNAs (shRNAs) targeting known chromatin regulators in a genetically defined AML mouse model, we identify the protein bromodomain-containing 4 (Brd4) as being critically required for disease maintenance. Suppression of Brd4 using shRNAs or the small-molecule inhibitor JQ1 led to robust antileukaemic effects in vitro and in vivo, accompanied by terminal myeloid differentiation and elimination of leukaemia stem cells. Similar sensitivities were observed in a variety of human AML cell lines and primary patient samples, revealing that JQ1 has broad activity in diverse AML subtypes. The effects of Brd4 suppression are, at least in part, due to its role in sustaining Myc expression to promote aberrant self-renewal, which implicates JQ1 as a pharmacological means to suppress MYC in cancer. Our results establish small-molecule inhibition of Brd4 as a promising therapeutic strategy in AML and, potentially, other cancers, and highlight the utility of RNA interference (RNAi) screening for revealing epigenetic vulnerabilities that can be exploited for direct pharmacological intervention.
AML represents a paradigm for understanding how complex patterns of cooperating genetic and epigenetic alterations lead to tumorigenesis 3, 4 . Although this complexity poses a challenge for the development of targeted therapies, diverse gene mutations in AML generally converge functionally to deregulate similar core cellular processes. One key event in AML initiation is the corruption of cell-fate programs to generate leukaemia stem cells that aberrantly self-renew and thereby maintain and propagate the disease 5 . Although it is incompletely understood, this process has been linked to changes in regulatory chromatin modifications 2 . For example, common AML oncogenes such as those encoding the AML1-ETO and MLL fusion proteins induce self-renewal programs at least in part through reprogramming of epigenetic pathways 6, 7 . In addition, several genes encoding epigenetic regulators have been identified as targets of somatic mutation in AML 8, 9 . Because epigenetic alterations induced by oncogenic stimuli are potentially reversible, chromatin regulators are being explored as candidate drug targets 1 . To probe epigenetic pathways required for AML maintenance systematically, we built a custom shRNA library targeting 243 known chromatin regulators, including most 'writers', 'readers' and 'erasers' of epigenetic marks (Supplementary Fig. 1 and Supplementary Table 1 ). This library of 1,094 shRNAs (3-6 per gene) was constructed in TRMPV-Neo, a vector optimized for negative-selection RNAi screening, and was transduced as one pool into an established Tet-oncompetent AML mouse model driven by MLL-AF9 and Nras G12D (ref. 10). After drug selection, shRNA expression was induced by addition of doxycycline, and changes in library representation after 14 days of culture were monitored using deep sequencing of shRNA guide strands amplified from genomic DNA ( Fig. 1a and Supplementary  Fig. 2 ). Using the scoring criterion of more than twenty-fold depletion in each of two independent replicates, 177 shRNAs were strongly depleted. These included all eight positive-control shRNAs targeting essential genes (Rpa1, Rpa3, Pcna and Polr2b), as well as several shRNAs targeting two known MLL-AF9 cofactors (Men1 and Psip1) 11, 12 . Genes for which at least two independent shRNAs scored were subjected to extensive one-by-one validation using an independent MLL-AF9/ Nras G12D AML cell line and vector system ( Supplementary Fig. 3a) . In both the primary screen and validation stages, several shRNAs targeting Brd4 were among the most strongly depleted, identifying this gene as the top scorer in the screen (Fig. 1a and Supplementary Fig. 3b ).
Brd4 is a member of the BET family of bromodomain-containing proteins that bind to acetylated histones to influence transcription 13 . BRD4 is also a proto-oncogene that can be mutated via chromosomal translocation in a rare form of squamous-cell carcinoma 14 , although a role in leukaemia has not been described. The recent development of small-molecule BET bromodomain inhibitors 15, 16 , together with our screening results, prompted us to investigate the suitability of Brd4 as an AML drug target. Five independent Brd4 shRNAs showed a close correspondence between knockdown efficiency and growth inhibition, indicating on-target effects (Fig. 1b) . Suppression of Brd4 led to cellcycle arrest and apoptosis of leukaemia cells, whereas the equivalent knockdown in immortalized murine embryonic fibroblasts (MEFs) led to only modest cell-cycle inhibition without cytotoxicity (Supplementary Fig. 4a-d ). Brd4 knockdown also failed to influence the growth of non-transformed G1E erythroblast cells ( Supplementary Fig. 4e ). In addition, shRNAs targeting BRD4 were sufficient to induce cell-cycle arrest in two MLL-AF9 1 human AML lines ( Supplementary Fig. 5 ). Together, these results indicate that Brd4 is a critical requirement in MLL-AF9-induced AML.
Next, we examined the sensitivity of leukaemia cells to JQ1, a firstin-class small-molecule inhibitor of BET bromodomains with highest affinity for the first bromodomain of Brd4 (ref. 15) . Proliferation of mouse MLL-fusion leukaemia cells was notably sensitive to submicromolar JQ1 concentrations, as compared to proliferation of fibroblasts and G1E cells (Fig. 1c) , correlating with the relative impact of Brd4 shRNAs on proliferation of these different cell types. We also examined growth-inhibitory effects of JQ1 in a series of established human leukaemia cell lines as well as in adult and paediatric primary leukaemia samples. We observed broad growth-suppressive activity of JQ1 (IC 50 , 500 nM) in 13 out of 14 AML cell lines ( Fig. 1d and Supplementary Fig. 6a, b ) and in 12 out of 15 primary human AML samples, representing diverse disease subtypes ( Supplementary Fig.  7, 8 ). In addition, all three primary MLL-rearranged infant leukaemias tested were sensitive to JQ1 ( Supplementary Fig. 8 ), whereas other non-AML-leukaemia and solid-tumour cell lines showed minimal sensitivity to the compound ( Fig. 1d and Supplementary Fig. 6c ). In all AML lines examined, JQ1 treatment triggered cell-cycle arrest and apoptosis, similar to the effects seen upon shRNA-mediated Brd4 knockdown (Fig. 1e, f and Supplementary Figs 7-9 ). Together, these data indicate a critical requirement for Brd4 in AML proliferation that can be effectively inhibited using the bromodomain inhibitor JQ1.
We next investigated the relevance of Brd4 to AML progression in vivo. To suppress Brd4 in established AML in mice, Tet-on-competent MLL-AF9/Nras G12D leukaemia cells were transduced with TRMPVNeo constructs containing Brd4 shRNAs or control shRNAs, and transplanted into secondary recipient mice ( Supplementary Fig. 10 ). After disease onset, confirmed by bioluminescent imaging, shRNA expression was induced by doxycycline administration. Subsequent monitoring showed that Brd4 knockdown resulted in a marked delay in leukaemia progression and a survival benefit (Fig. 2a-c and Supplementary Fig. 11 ). Taking advantage of the dsRed reporter linked to shRNA expression in the TRMPV-Neo vector 10 , flow-cytometry analysis verified that Brd4-shRNA-positive cells were depleted in the terminal leukaemia burden as compared to controls, indicating that the mice succumbed to an outgrowth of Brd4-shRNA-negative cells (Fig. 2d, e) . Together, these data indicate that RNAi-mediated suppression of Brd4 inhibits leukaemia progression in vivo.
To examine whether JQ1 has single-agent activity in AML, mice transplanted with MLL-AF9/Nras G12D leukaemia cells were treated either with daily injections of JQ1 (50 mg kg
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) or with vehicle. JQ1 administration led to a marked delay in disease progression and significantly extended survival (Fig. 2f-h ). JQ1 also showed single-agent activity in an intervention setting, in which treatment was initiated only after disease was detected by bioluminescent imaging (Fig. 2i and Supplementary Fig. 12 ). Comparable effects were observed in an independent AML mouse model based on expression of AML1-ETO9a and Nras G12D and loss of p53 (ref. 17) , which is known to be insensitive to conventional chemotherapy ( Supplementary Fig. 13 ). Consistent with previous findings 15 , JQ1 treatment was well tolerated in mice, with little if any impact on normal haematopoiesis ( Supplementary  Figs 14-16 ). Collectively, these findings demonstrate that JQ1 has potent and leukaemia-specific effects as a single agent in vivo.
AML is characterized by an expanded self-renewal capacity linked with an inability to complete terminal myeloid differentiation. Therefore, we next considered whether Brd4 influences the differentiation state of leukaemia cells. Both expression of Brd4 shRNA and JQ1 treatment altered the morphology of MLL-AF9/Nras G12D leukaemia from myelomonocytic blasts to cells with a macrophage-like appearance (Fig. 3a, b and Supplementary Fig. 17a ). Upon Brd4 inhibition, 
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leukaemia cells showed increased surface expression of integrin aM (Itgam, also known as Mac-1), a myeloid differentiation marker, and decreased expression of Kit, a marker associated with leukaemia stem cells (LSCs) in mouse models of MLL-rearranged leukaemia (Fig. 3c, d and Supplementary Fig. 17b , c) 18, 19 . In addition, JQ1 treatment induced morphological signs of maturation phenotypes in most of the primary leukaemia samples tested, albeit to varying degrees ( Supplementary  Figs 7 and 8 ).
To further investigate whether suppression of Brd4 affects the LSC compartment, we performed gene set enrichment analysis (GSEA) of expression microarray data obtained from Brd4-shRNA-treated and JQ1-treated leukaemia cells 20 . GSEA revealed a marked upregulation of macrophage-specific gene expression after Brd4 inhibition (Fig. 3e, f) , as well as global downregulation of a gene expression signature previously shown to discriminate LSCs from non-self-renewing leukaemia cell populations (Fig. 3g, h ) 21 . A similar profile of gene expression changes was seen after JQ1 treatment of THP-1 cells, a human MLL-AF9-expressing AML cell line ( Supplementary Fig. 18 ). Although we cannot exclude the involvement of additional cellular targets, the strong concordance between phenotypes induced by Brd4 shRNAs and JQ1 supports Brd4 as the relevant target of JQ1 in AML. Together, these findings indicate that Brd4 is critically required to maintain LSC populations and prevent terminal myeloid differentiation.
Recent evidence indicates that the Myc transcriptional network has an important role in LSC self-renewal 22, 23 . Because previous studies also implicate Myc as a potential downstream target of Brd4 (refs 24, 25), we examined whether this regulatory function was relevant to the antileukaemic effects of JQ1. Brd4 inhibition with shRNAs or JQ1 led to a Statistical significance compared to shRen was calculated using a log-rank test; *, P 5 0.0001; **, P , 0.0001. ) or DMSO carrier. g, Quantification of bioluminescent imaging responses to JQ1 treatment. Mean values of six DMSO-and seven JQ1-treated mice are shown. P values were calculated using a two-tailed Student's t-test. h, Kaplan-Meier survival curves of control and JQ1-treated mice. Statistical significance was calculated using a log-rank test. In f, g and h, JQ1 treatment was initiated on day 1 after transplant of 50,000 leukaemia cells. i, Quantification of bioluminescent imaging responses to JQ1 treatment in established disease. Treatment of leukaemic mice was initiated 6 days after transplant, when disease first became detectable by imaging. Mean values of six DMSO-and seven JQ1-treated mice are shown. P values were calculated using a two-tailed Student's t-test. All error bars represent s.e.m. 1 cells (shRen versus three different Brd4 shRNAs) after 2 days of doxycycline induction. In f and h, microarray data were obtained from leukaemia cells treated for 2 days with DMSO or 100 nM JQ1. NES, normalized enrichment score; FDR q-val, false discovery rate q-value (the probability that a gene set with a given NES represents a false-positive finding).
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marked reduction of mRNA and protein levels of Myc in MLL-AF9/ Nras G12D leukaemia, whereas these effects were minimal in MEF and G1E cells (Fig. 4a, b and Supplementary Fig. 19a-c) . Downregulation of Myc mRNA levels occurred within 60 min of JQ1 exposure, qualitatively preceding the increased expression of genes related to macrophage differentiation, such as Cd74 (Fig. 4c) . Supporting a direct role in Myc transcriptional regulation, chromatin immunoprecipitation (ChIP) experiments identified a region of focal Brd4 occupancy about 2 kilobases upstream of the Myc promoter and this was eliminated after exposure to competitive JQ1 (Fig. 4d) . As expected, RNAi-or JQ1-induced suppression of Brd4 led to a global reduction in expression of Myc target genes 22, 26 ( Supplementary Figs 19d and 20) . Notably, JQ1 treatment triggered Myc downregulation in a broad array of mouse and human leukaemia cell lines examined (Fig. 4a, b and Supplementary Fig. 21 ), indicating that JQ1 may provide a means to suppress the Myc pathway in a range of AML subtypes.
To evaluate whether suppression of Myc confers the growthinhibitory effects of JQ1, we generated MLL-AF9/Nras G12D leukaemia cultures in which the Myc cDNA was ectopically expressed from a retroviral promoter, which resulted in Myc expression levels that were only slightly elevated but entirely resistant to JQ1-induced suppression ( Fig. 4e and Supplementary Fig. 22a ). Ectopic Myc expression conferred nearly complete resistance to macrophage differentiation and cell-cycle arrest induced by JQ1 and Brd4 shRNAs (Fig. 4f, g and Supplementary Figs 22b and 23) . Furthermore, global gene-expression profiling revealed that most of the JQ1-induced transcriptional changes are probably secondary effects of Myc downregulation (Supplementary Fig. 24 ). Ectopic Myc expression was unable to prevent JQ1-induced cell death, indicating that Brd4 has Myc-independent roles in regulating cell survival ( Supplementary Fig. 22c, d ). These findings collectively support a role for Brd4 in maintaining Myc expression to preserve an undifferentiated cellular state in AML.
By taking a non-biased screening approach targeting epigenetic regulators, our study has identified Brd4 as a critical factor required for AML disease maintenance. Because Brd4 is not evidently mutated or overexpressed in AML ( Supplementary Fig. 25 ), the exquisite sensitivity of leukaemia cells to Brd4 inhibition would not have been revealed simply through genetic or transcriptional characterization of this disease. We further show that the bromodomain inhibitor JQ1 has broad activity in diverse AML contexts and, by comparing its effects to those induced by Brd4 shRNAs, we provide evidence that Brd4 is the primary target for the antileukaemic activity of JQ1. Of note, JQ1 is a first-generation chemical inhibitor yet to be optimized for in vivo delivery, with a half-life of only about 1 h in rodents (Supplementary Fig. 26 and ref. 15) . The more robust antileukaemic effects seen using Brd4 shRNAs in vivo indicate that second-generation derivatives of this compound may have greater clinical activity. Regardless, our results unambiguously highlight the utility of RNAi screening for revealing candidate drug targets in cancer.
As a competitive inhibitor of the acetyl-lysine binding domain, JQ1 interferes with the ability of Brd4 to 'read' histone acetylation marks that facilitate transcriptional activation 15 . When applied to leukaemia cells, JQ1 interferes with transcriptional circuits supporting self-renewal, thus targeting LSCs and inducing terminal differentiation. In a parallel study, we identified the transcription factor Myb as a critical mediator of addiction to the MLL-AF9 oncogene 31 . Notably, global gene-expression changes observed after genetic or pharmacological inhibition of Brd4 are remarkably similar to those seen upon suppressing Myb 31 , indicating that Myb and Brd4 may intersect functionally in a common transcriptional circuit that is essential for malignant self-renewal. A key downstream effector of both Myb and Brd4 is the oncoprotein Myc (ref. 27 ), which has been validated as an attractive therapeutic target but has thus far escaped efforts at pharmacological inhibition 28, 29 . Although the precise mechanism remains to be further defined, targeting Brd4 abolishes Myc expression and limits self-renewal, with selectivity for the malignant context, thus avoiding the haematopoietic toxicities that may be associated with systemic Myc inhibition 30 . As such, our study may define a general strategy to disarm oncogenic pathways through the direct modulation of the epigenetic machinery.
METHODS SUMMARY
Pooled negative-selection RNAi screening. A customized shRNA library targeting 243 chromatin-regulating mouse genes was designed using miR30-adapted BIOPREDsi predictions, and was generated by PCR-cloning a pool of oligonucleotides synthesized on 55k arrays (Agilent Technologies). Pools of shRNAs were subcloned into the TRMPV-Neo vector (Addgene catalogue no. 27990) together with control shRNAs, and transduced into Tet-on MLL-AF9/Nras G12D leukaemia cells for negative-selection screening, essentially as described previously 10 . All 
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shRNA sequences as well as primary screening data are provided in Supplementary Table 1 . Animal studies. All mouse experiments were approved by the Cold Spring Harbor animal care and use committee. For conditional RNAi experiments in vivo, Tet-on MLL-AF9/Nras G12D leukaemia cells were transduced with TRMPVNeo-shRNA constructs, followed by transplantation into sub-lethally irradiated recipient mice, as described previously 10 . For shRNA induction, animals were treated with doxycycline in both drinking water (2 mg ml 21 with 2% sucrose; Sigma-Aldrich) and food (625 mg kg
21
, Harlan laboratories). For JQ1 treatment trials, a stock of 100 mg ml 21 JQ1 in DMSO was diluted 20-fold by dropwise addition of a 10% 2-hydroxypropyl-b-cyclodextrin carrier (Sigma) under vortexing, yielding a 5 mg ml 21 final solution. Mice were intraperitoneally injected daily with freshly diluted JQ1 (50 or 100 mg kg
) or a similar volume of carrier containing 5% DMSO. Microarray analysis. Expression microarrays were performed using Affymetrix ST 1.0 GeneChips. Raw microarray data can be accessed at Gene Expression Omnibus, GSE29799. Pathway analysis was performed using GSEA v2.07 software with 1,000 phenotype permutations 20 . All gene sets used for GSEA are provided in Supplementary Table 2 . 
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METHODS
Pooled negative-selection RNAi screening. A custom shRNA library targeting 243 chromatin-regulating mouse genes was designed using miR30-adapted BIOPREDsi predictions (six shRNAs per gene) and constructed by PCR-cloning a pool of oligonucleotides synthesized on 55k customized arrays (Agilent Technologies) as previously described 10 . After sequence verification, 1,094 shRNAs (3-6 per gene) were combined with several positive-and negative-control shRNAs at equal concentrations in one pool. This pool was subcloned into TRMPV-Neo and transduced into Tet-on MLL-AF9/Nras G12D leukaemia cells using conditions that predominantly lead to a single retroviral integration and represent each shRNA in a calculated number of .500 cells (a total of thirty million cells at infection, 2% transduction efficiency). Transduced cells were selected for 5 days using 1 mg ml 21 G418 (Invitrogen); at each passage more than twenty million cells were maintained to preserve library representation throughout the experiment. After drug selection, T0 samples were obtained (,twenty million cells per replicate) and cells were subsequently cultured with 0.5 mg ml 21 G418 and 1 mg ml 21 doxycycline to induce shRNA expression. After 14 days (12 passages, T14), about fifteen million shRNA-expressing (dsRed 1 /Venus 1 ) cells were sorted for each replicate using a FACSAriaII (BD Biosciences). Genomic DNA from T0 and T14 samples was isolated by two rounds of phenol extraction using PhaseLock tubes (5prime) followed by isopropanol precipitation. Deep-sequencing template libraries were generated by PCR amplification of shRNA guide strands as previously described 10 . Libraries were analysed on an Illumina Genome Analyser at a final concentration of 8 pM; 18 nucleotides of the guide strand were sequenced using a custom primer (miR30EcoRISeq, TAGCCCCTTGAATTCCGAGGCAGTAGGCA). To provide a sufficient baseline for detecting shRNA depletion in experimental samples, we aimed to acquire .500 reads per shRNA in the T0 sample, which required more than ten million reads per sample to compensate for disparities in shRNA representation inherent in the pooled plasmid preparation or introduced by PCR biases. With these conditions, we acquired T0 baselines of .500 reads for 1,072 (97% of all) shRNAs. Sequence processing was performed using a customized Galaxy platform 32 . For each shRNA and condition, the number of matching reads was normalized to the total number of library-specific reads per lane and imported into a database for further analysis (Access 2003, Microsoft). All shRNA sequences are provided in Supplementary Table 1 . Animal studies. All mouse experiments were approved by the Cold Spring Harbor animal care and use committee. Leukaemia cells were transplanted by tail-vein injection of 1 3 10 6 cells into sub-lethally (5.5 Gy) irradiated B6/SJL(CD45.1) recipient mice. For whole-body bioluminescent imaging, mice were intraperitoneally injected with 50 mg kg 21 D-Luciferin (Goldbio), and after 10 min, analysed using an IVIS Spectrum system (Caliper LifeSciences). Quantification was performed using Living Image software (Caliper LifeSciences) with standardized rectangular regions of interests covering the mouse trunk and extremities. For shRNA induction, animals were treated with doxycycline in both drinking water (2 mg ml 21 with 2% sucrose; Sigma-Aldrich) and food (625 mg kg
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, Harlan laboratories). For JQ1 treatment trials, a stock of 100 mg ml 21 JQ1 in DMSO was 20-fold diluted by dropwise addition of a 10% 2-hydroxypropyl-b-cyclodextrin carrier (Sigma) under vortexing, yielding a 5 mg ml 21 final solution. Mice were intraperitoneally injected daily with freshly diluted JQ1 (50 or 100 mg kg
) or a similar volume of carrier containing 5% DMSO. Plasmids. For conditional RNAi experiments, shRNAs were expressed from either the TRMPV-Neo vector or the TtTMPV-Neo vector, which have been described previously (and are available as Addgene catalogue nos 27990 and 27993) 10 . For screen validation, shRNAs were cloned into LMN(MSCV-miR30-PGK-NeoR-IRES-GFP), which was generated from LMP 33 by replacing the PuroR transgene with a NeoR cassette. For Myc rescue experiments, the wild-type mouse Myc cDNA was subcloned into MSCV-PGK-Puro-IRES-GFP (MSCV-PIG) 34 . Cell culture. All mouse MLL-leukaemia cell lines were derived from bone marrow obtained from terminally ill recipient mice, and were cultured in RPMI 1640 (Gibco-Invitrogen) supplemented with 10% FBS, 100 U ml 21 penicillin and 100 mg ml 21 streptomycin. MLL-AF9(alone), MLL-AF9/Nras G12D , Tet-on MLL-AF9/ Nras G12D and MLL-ENL/FLT3 ITD cell cultures were derived as described previously 10, 17 . Tet-on immortalized MEF cultures were described previously 10 . G1E cells were provided by M. Weiss. MEF cells were grown in DMEM with 10% FBS, 100 U ml 21 penicillin, 100 mg ml 21 streptomycin and 1% glutamine (GIBCO). G1E cells were grown in IMDM with 15% FBS, 100 U ml 21 penicillin, 100 mg ml 21 streptomycin, 2 U ml 21 erythropoietin (Sigma) and 10% Kit-ligand-conditioned medium. All human leukaemia cell lines were cultured in RPMI-1640 with 10% FBS, 100 U ml 21 penicillin and 100 mg ml 21 streptomycin, except KASUMI-1 cells, which were cultured in 20% FBS. NOMO-1, MOLM-13, EoL-1, NB4, HNT-34 and CMK were purchased from Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ). KASUMI-1, HL-60, MV4-11, KG1, HEL, THP-1, B16-F10 and IMR-90 were obtained from ATCC. K-562 cells were provided by M. Carroll. U2OS, HeLa and Jurkat were provided by the CSHL tissue culture facility. CD34.MA9.NRAS and CD34.MA9.FLT3 cells were generated by retroviral transduction of umbilical-cord-blood CD34 1 cells as described previously 35, 36 . All retroviral packaging was performed using ecotropic Phoenix cells according to established protocols (http://www.stanford.edu/group/ nolan/tutorials/retpkg_1_packlines.html). Western blotting. For Brd4 immunoblotting, 30 mg of whole-cell lysate RIPA extracts (25 mM Tris (pH 7.6), 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS) were loaded into each lane. For Myc immunoblotting, cells were lysed directly in Laemmli buffer and about 50,000 cell-equivalents were loaded into each lane. Protein extracts were resolved by SDS polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose for blotting. Proliferation assay. Competitive proliferation assays using shRNAs in LMN or TRMPV-/TtRMPV-Neo vectors were performed as outlined in Supplementary  Fig. 3a and as described previously 10 , respectively. Proliferation assays for JQ1 in vitro testing were performed by counting the increase in viable cell numbers over 72 h in the presence of different JQ1 concentrations. Dead cells were excluded using propidium iodide (PI) staining. Measurements of cell concentration were performed on a Guava Easycyte (Millipore), gating only viable cells (FSC/SSC/ PI 2 ). Proliferation rates were calculated using the equation ln(cell concentration at 72 h/cell concentration at 0 h)/72. Relative proliferation rates were calculated by normalizing to the rate of DMSO-treated cells. May-Grünwald-Giemsa cytospin staining. MLL-AF9/Nras G12D leukaemia cells were treated with 1 ug ml 21 doxycycline for 2 days to induce shRNA expression from TRMPV-Neo or TtTMPV vectors, or treated with 100 nM JQ1 for 2 days. 50,000 cells were resuspended in 100 ml FACS buffer (5% FBS, 0.05% NaN 3 in PBS) and cytospun onto glass slides using a Shandon Cytospin 2 Centrifuge at 500 rpm for 5 min. May-Grünwald (Sigma) and Giemsa (Sigma) stainings were performed according to manufacturer's protocols. Images were collected using a Zeiss Observer Microscope with a 340 objective. BrdU cell-cycle analysis and annexin V flow cytometry. BrdU incorporation assays were performed according to the manufacturer's protocol (BD, APC BrdU flow kit), with cells pulsed with BrdU for 30 min. Cells were co-stained with 7-aminoactinomycin D or 49,6-diamidino-2-phenylindole (DAPI) for DNA content measurement. For all conditional shRNA experiments, the analysis was gated on Venus ). All analyses were performed using FlowJo software (Tree Star). shRNA experiments in human AML cell lines. THP-1 and MOLM-13 cells were modified to express the ecotropic receptor and rtTA3 using retroviral transduction of MSCV-RIEP (MSCV-rtTA3-IRES-EcoR-PGK-Puro) followed by drug selection (0.5 and 1 ug ml 21 puromycin for 1 week, respectively). The resulting cell lines were transduced with ecotropically packaged TRMPV-Neo-shRNA retroviruses, selected with 400 mg ml 21 G418 for 1 week and treated with 1 mg ml 21 doxycycline to induce shRNA expression. The relative change in Venus 1 /dsRed 1 (shRNA 1 1) cells was monitored on a Guava Easycyte (Millipore). BrdU cell-cycle analysis was performed as described above. Adult primary leukaemia sample analysis. The study was approved by the Institutional Review Board (ethics committee) of the Medical University of Vienna. Primary leukaemic cells were obtained from peripheral blood or bone marrow aspirate samples. Informed consent was obtained before blood donation or bone marrow puncture in each case. Diagnoses were established according to criteria provided by the French-American-British (FAB) cooperative study group 37, 38 and the World Health Organization (WHO) 39 . Mononuclear cells were prepared using Ficoll and stored in liquid nitrogen until used. HL60 and MOLM13 cell lines (obtained from DSMZ) were included as controls. After thawing, the viability of AML cells ranged from 70% to 99% as assessed by trypan blue exclusion. Primary cells (thawed mononuclear cells, 5-10 3 10 4 cells per well) and cell lines (1-5 3 10 4 cells per well) were cultured in 96-well microtitre plates (TPP) in RPMI-1640 medium (PAA laboratories) with 10% fetal calf serum (FCS, Pasching) in the absence or presence of JQ1 (10-5,000 nM) at 37 uC (5% CO 2 ) for 48 h. In selected experiments, primary AML cells were incubated with JQ1 in the presence or absence of a cocktail of proliferation-inducing cytokines: recombinant human (rh) G-CSF, 100 ng ml 21 (Amgen), rhSCF, 100 ng ml 21 (Peprotech) and rhIL-3, 100 ng ml 21 (Novartis). After 48 h, 0.5 mCi
